Form 4 for GILD Gilead Sciences
Accepted 2024-11-29 00:00:00 ET · period of report 2024-11-27 · accession 0001127602-24-028232 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-11-29 | 2024-11-27 | GILD | Parsey Merdad | Chief Medical Off | S - Sale+OE | $91.92 | -164.2K | 99.6K | -62% | -$15.09M |
| DM | 2024-11-29 | 2024-11-27 | GILD | Parsey Merdad | Chief Medical Off | M - OptEx | $62.44 | +145.4K | 156.9K | +1,267% | +$9.08M |
| DM | 2024-11-29 | 2024-11-27 | GILD | Parsey Merdad | Chief Medical Off | M - OptEx | $0.00 | -145.4K | 196 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-27 | S | D | 57,294 | $91.79 | 187,718 | D | — | — | (F1) Sale prices reported for the transactions reported here range from $91.451 to $92.095. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| 2 | Common | Common Stock | 2024-11-27 | M | A | 88,119 | $65.38 | 245,012 | D | — | — | |
| 3 | Common | Common Stock | 2024-11-27 | S | D | 10,399 | $92.00 | 80,801 | D | — | — | |
| 4 | Common | Common Stock | 2024-11-27 | S | D | 3,199 | $91.80 | 91,200 | D | — | — | (F3) Sale prices reported for the transactions reported here range from $91.451 to $92.035. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| 5 | Common | Common Stock | 2024-11-27 | S | D | 5,200 | $91.80 | 94,399 | D | — | — | (F2) Sale prices reported for the transactions reported here range from $91.458 to $92.04. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. |
| 6 | Common | Common Stock | 2024-11-27 | S | D | 88,119 | $92.00 | 99,599 | D | — | — | |
| 7 | Common | Common Stock | 2024-11-27 | M | A | 57,294 | $57.92 | 156,893 | D | — | — | |
| 8 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-11-27 | M | D | 57,294 | $0.00 | 64,376 | D | $57.92 · — to 2032-03-10 | 57,294 Common Stock | (F4) The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 9 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-11-27 | M | D | 88,119 | $0.00 | 196 | D | $65.38 · — to 2029-11-10 | 88,119 Common Stock | (F4) The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |